Novo Nordisk defends next-gen obesity drug CagriSema, gives …
22 hours ago · The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly emerges as a strong …
Novo outlines new late-stage study of obesity drug CagriSema
1 day ago · Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said …
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek …
2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that …
Novo Nordisk to seek regulatory approval for CagriSema obesity …
1 day ago · Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly …
Investors grow anxious at Novo Nordisk's silence over CagriSema …
1 day ago · Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results BY Ryan Hogg Novo Nordisk is set to release annual …
Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)
Jan 27, 2025 · A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients …
Novo Nordisk A/S: CagriSema demonstrates superior weight
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) …
Novo Nordisk’s next-generation weight-loss drug CagriSema …
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with …
Investors Seek Answers on Novo Nordisk's Next-Gen Obesity Drug CagriSema
2 days ago · Reuters interviewed two people who participated in the CagriSema trial that reported in December, called REDEFINE-1, and three in an ongoing Phase III trial, called REDEFINE …